About Calistoga

Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.

Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting the isoforms of the PI3 kinase pathway.

Calistoga Pharmaceuticals is a private, venture backed company with top tier investors including Frazier Healthcare, Alta Partners, Three Arch, and Amgen Ventures. The company is led by a seasoned management team, all with experience developing successful commercialized products.

With a portfolio of isoform-select PI3K inhibitors, Calistoga Pharmaceuticals is uniquely positioned to be the first company to demonstrate the clinical benefit of these PI3 kinase inhibitors in patients with cancer and inflammatory diseases.